EktaH Advances NKS-3 into Phase II Clinical Development for Obesity, Secures €2.4 Million Funding

EktaH Advances NKS-3 into Phase II Clinical Development for Obesity, Secures €2.4 Million Funding

EktaH, a clinical-stage biotechnology company developing oral therapies for obesity and metabolic diseases, has advanced its lead candidate NKS-3 into Phase II clinical development. The company has enrolled the first participant in its exploratory Phase IIa SERENITY-1 study (NCT07882654), which is being conducted in Tunisia.

Alongside this clinical milestone, EktaH has secured €2.4 million in non-dilutive funding from Bpifrance to support the further development of NKS-3, including preparations for a larger Phase II clinical study planned in France.

Key Highlights

  • NKS-3 advances into Phase II clinical development for obesity.

  • First participant enrolled in the Phase IIa SERENITY-1 study in Tunisia.

  • SERENITY-1 plans to recruit approximately 31 adults with obesity.

  • Topline results are expected in Q1 2027.

  • EktaH secures €2.4 million in non-dilutive funding from Bpifrance.

  • A larger Phase II programme will investigate NKS-3 as a standalone obesity treatment and as a potential maintenance therapy after GLP-1 treatment discontinuation.

SERENITY-1 Phase IIa Study: Evaluating NKS-3 in Obesity

The SERENITY-1 study is a randomised, single-blind, placebo-controlled exploratory Phase IIa trial evaluating NKS-3 in adults with obesity. It is being conducted at the Institut National de Nutrition de Tunis in Tunisia.

The study plans to enrol approximately 31 participants, who will be randomised in a 2:1 ratio to receive NKS-3 or matching placebo. Participants will self-administer the treatment for 90 days.

The investigational regimen is 7.5 mg twice daily, corresponding to a total daily dose of 15 mg.

The primary endpoint is the percentage change in body weight from baseline to Day 90. Secondary and exploratory assessments include:

  • Changes in sensitivity to linoleic acid, a fatty acid associated with oral fat perception.

  • Safety and tolerability of NKS-3.

  • Changes in fat mass and skeletal muscle mass.

  • Composition of weight loss.

Topline results from SERENITY-1 are expected in Q1 2027.

€2.4 Million Bpifrance Funding to Support Clinical Development

EktaH has secured €2.4 million in non-dilutive funding through a Bpifrance programme to support key development activities for NKS-3.

The funding will support:

  • A 90-day toxicology study.

  • Chemistry, manufacturing and controls (CMC) activities.

  • Phase II clinical development.

The funding package comprises equal parts grant funding and reimbursable advances. Disbursement will take place in phases, subject to predefined annual stage gates and the achievement of development and regulatory milestones.

The financial support is expected to help EktaH progress its clinical programme and prepare for a larger Phase II study in France.

Expanded Phase II Programme: Standalone Treatment and Post-GLP-1 Maintenance

Beyond SERENITY-1, EktaH is planning a broader Phase II clinical programme to investigate NKS-3 in two potential treatment settings:

  1. Monotherapy for weight loss: Evaluating NKS-3 as a standalone treatment for adults with obesity.

  2. Weight maintenance after GLP-1 treatment: Investigating whether NKS-3 can help maintain weight loss following discontinuation of GLP-1 therapy.

The planned multicentre, randomised, dose-finding studies will assess different dosing regimens and their potential effects on body weight and fat mass while preserving lean body mass.

One planned study is expected to enrol approximately 100 adults with obesity. It will compare two NKS-3 dosing regimens with placebo in a double-blind, randomised design. Treatment is expected to last 12 weeks, followed by a 12-week off-treatment follow-up.

EktaH aims to submit the Clinical Trial Application in early 2027 and enrol the first participant in the second half of 2027. Final study designs remain subject to applicable regulatory and ethics approvals.

Phase I Study: Preliminary Safety Findings

EktaH is also completing its Phase I study, which enrolled 120 adults with obesity across single- and multiple-ascending-dose cohorts.

The randomised, single-blind, placebo-controlled, single-centre study evaluated NKS-3 and NKS-5, two modified linoleic acids, including their effects on body weight and oral fat sensitivity.

Preliminary data from 22 participants who received NKS-3 for 30 days showed no serious adverse events considered related to NKS-3 reported to date.

The company expects to lock the Phase I database by the end of November 2026, with final results and the Clinical Study Report expected in Q1 2027. The complete analysis is expected to provide further information on safety and preliminary efficacy and help guide the Phase II programme.

How NKS-3 Works

NKS-3 is an orally administered modified fatty acid molecule designed to reactivate two fat taste receptors, CD36 and GPR120, located in the tongue epithelium. These receptors are reported to be downregulated in many individuals with obesity.

The candidate is designed to restore the activity of these receptors and stimulate the body's natural release of satiety hormones, including:

  • GLP-1 (glucagon-like peptide-1)

  • CCK (cholecystokinin)

  • PYY (peptide YY)

By activating these endogenous signalling pathways, NKS-3 aims to regulate appetite and reduce food intake without administering external satiety hormones.

Preclinical Findings Suggest Potential for Weight Maintenance

Earlier preclinical studies in diet-induced obese mice showed approximately 50% less weight rebound following semaglutide discontinuation in animals receiving NKS-3 compared with control animals. The findings also indicated preservation of lean body mass.

These results support the investigation of NKS-3 as a potential standalone obesity treatment and as a maintenance approach after GLP-1 therapy. However, these benefits have not yet been established in human clinical trials.

NKS-3 has also demonstrated anti-inflammatory activity in experimental models, including reductions in key pro-inflammatory cytokines and modulation of central inflammatory signalling pathways. Further research will be needed to determine whether these effects translate into clinical benefits for people with obesity and metabolic diseases.

What This Development Means

The advancement of NKS-3 into Phase II marks an important step in EktaH's clinical development programme. The candidate is being investigated through a distinct approach that targets oral fat taste receptors and the body's endogenous satiety signalling pathways.

With the SERENITY-1 study underway and additional funding secured, EktaH is preparing to evaluate NKS-3 across both standalone weight-loss treatment and potential post-GLP-1 weight-maintenance settings.

The upcoming clinical results will be important in determining whether the promising preclinical findings and proposed mechanism translate into meaningful benefits for people living with obesity.

Found this useful? Share it with your team.

Welcome Back Sign in to Continue

Don't Have an Account? Sign Up!
Forgot Password?

Create your Account!

Don't Have an Account? Sign Up!